Status:

RECRUITING

Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI

Lead Sponsor:

Kiyuk Chang, MD,PhD

Conditions:

Myocardial Infarction

Statin Adverse Reaction

Eligibility:

All Genders

19+ years

Phase:

PHASE4

Brief Summary

Combination therapy of rosuvastatin 5mg and ezetimibe 10 mg showed similar achievement rate in decreasing LDL cholesterol level by 50% as single use of rosuvastatin 20 mg. This trial aims to prove no...

Detailed Description

IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) study showed that even when statin is not used as a treatment the rate of decrease of LDL cholesterol is correlated to...

Eligibility Criteria

Inclusion

  • Adults Aged 19 and up
  • Patients diagnosed with myocardial infarction (both ST segment elevation and non-ST segment elevation) who were treated with percutaneous coronary intervention (Myocardial infarction defined as in the 4th Universal Definition of Myocardial Infarction)
  • For female patients who are of childbearing age, subjects that agreed on taking mandatory pregnancy test
  • Patients who agreed and signed on the informed consent form

Exclusion

  • Patients with life expectancy of a year or less due to malignancy
  • Patients with chronic liver disease
  • Patients with sensitivity to active ingredient of the research drugs (ezetimibe and/or rosuvastatin) or patients who are prohibited to take ezetimibe and/or rosuvastatin.
  • Pregnant and/or breastfeeding
  • Female patients who are unable to use any means of contraception
  • Patients receiving hemodialysis, peritoneal dialysis patients and/or kidney transplant patients, due to end stage renal disease
  • Patients who participated in other clinical trial(s) within 3 months from the screening (except non-interventional observational study)
  • Patients considered inappropriate for the study for any other reason(s) by the inspector(s)

Key Trial Info

Start Date :

October 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 30 2027

Estimated Enrollment :

3548 Patients enrolled

Trial Details

Trial ID

NCT04499859

Start Date

October 1 2020

End Date

August 30 2027

Last Update

July 30 2025

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

Bucheon St.Mary Hospital

Bucheon-si, Gyeonggido, South Korea

2

St.Vincent's Hospital

Suwon, Gyeonggido, South Korea

3

Uijeongbu St.Mary's Hospital

Uijeongbu-si, Gyeonggido, South Korea

4

Daejeon St.Mary's Hospital

Daejeon, South Korea